- Combining Lilly and Amylin drug with insulin intake found to promote weight loss
- Sanofi presents study data at American Diabetes Association’s 71st Scientific Sessions
- Novo Nordisk wins 2010 Good Design Award for NovoPen Echo
- Insulin combination treats low blood sugar in diabetes patients, study finds
- Study: Sanofi insulin reduces weight gain, increases blood sugar control
PITTSBURGH — Mylan and Biocon have a deal to develop and sell generic insulin-analog products for diabetes, Mylan said.
Under the deal, Mylan will have the rights to develop and market Biocon's Glargine, Lispro and Aspart, respectively generic versions of Sanofi's Lantus, Eli Lilly's Humalog and Novo Nordisk's NovoLog.
"This collaboration builds off our existing successful partnership for generic biologics with Biocon and brings Mylan a portfolio of high-value insulin analog products," Mylan CEO Heather Bresch said. "This collaboration further expands and diversifies our pipeline of complex, difficult-to-manufacture products with strong future growth potential."